/
Oncology
Advanced Cancer
69
Pipeline Programs↗
55
Active Trials↗
69
Companies Involved↗
Advanced Cancer is a moderately active landscape with 69 programs across 69 companies. The most active players are TORL Biotherapeutics, LLC, Arcus Biosciences, Volastra Therapeutics, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 141
Phase 222
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
87%
Small molecule
58 of 67 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 67 classified programs, each share of the total. Modality classified for 99% of 69 pipeline programs.
Analysis
Trial Status
380
clinical trials
Completed244 · 64%
Terminated59 · 16%
Recruiting25 · 7%
Active, not recruiting23 · 6%
Withdrawn11 · 3%
Unknown status9 · 2%
Other9 · 2%
Clinical Trials
Trial Activity
380 trials
Page 1 of 26
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)